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Latency-associated nuclear antigen 1 (LANA1) of Kaposi’s sarcoma-associated herpesvirus (KSHV) is
implicated in the persistence of the viral genome during latent infection. It has been suggested that LANA1
tethers the viral genome to the host chromosome and also participates actively in DNA replication from the
terminal repeat of KSHV. Here we show by mutational analysis that the mitotic chromosome-binding activity
of LANA1 is tightly coupled to its replication activity. Thus, KSHV appears to have evolved a unique tactic for
its stable maintenance.
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the eti-
ological agent of Kaposi’s sarcoma and some lymphoprolifera-
tive diseases (9, 11, 47); it is closely related to Epstein-Barr
virus (EBV) and herpesvirus saimiri. The circularized viral
genome is maintained as an extrachromosomal element in
latently infected cells, whereas the linearized form of the viral
genome is packaged into infectious virus particles during lytic
infection (10, 16). Latency-associated nuclear antigen 1
(LANA1) is a viral protein expressed during latent infection
(22, 33, 51, 55). As a transcriptional modulator, LANA1 inter-
acts with several cellular transcription factors and influences
the activity of viral and cellular promoters (3, 20, 23, 25, 30, 35,
36, 40, 41, 50, 54). When tethered to promoters via a heterol-
ogous DNA-binding domain, LANA1 acts as a transcriptional
repressor, possibly by interacting with the mSin3 complex and
heterochromatin protein 1 (36, 43, 57). As a replication factor,
LANA1 colocalizes with the viral genome on the host chro-
mosome and has been shown to be responsible for the stable
maintenance of plasmids containing the KSHV terminal re-
peat (TR); it may therefore link the viral genome to a host
chromosome, retaining the viral genome in the nucleus during
mitosis and permitting equipartition to the progeny (5, 14).
The chromosome-binding activity of LANA1 has been mapped
to its N-terminal 22 amino acids and has been designated the
chromosome-binding sequence (CBS) (49). Its C terminus
binds to sequences within the TRs located at both ends of the
KSHV genome and represses TR-dependent transcription (6,
15, 24, 42). As expected from the chromosome-tethering
model, the LANA1 CBS is necessary for long-term replication
of a KSHV TR-containing plasmid (59). In addition, we and
others have shown that LANA1 is required for the transient
replication of KSHV TR-containing plasmids, indicating that it
may play an essential role not only in plasmid maintenance but
also in DNA replication from the KSHV TR (26, 28, 42). Using
a panel of LANA1 deletion mutants, we found that the CBS is
necessary and sufficient for the C-terminal DNA-binding do-
main to support the replication of a KSHV TR-containing
plasmid, suggesting that LANA1 must bind to the chromosome
to fulfill its replication function (C. Lim, T. Seo, J. Jung, and
J. Choe, submitted for publication). To examine this possibility
further, we have generated several LANA1 derivatives with
point mutations in their CBS and characterized their activities.
We reasoned that, because of its functional importance, the
LANA1 CBS may be evolutionarily conserved among herpes-
viruses. Multiple sequence alignment of herpesvirus LANA1
homologues disclosed a few conserved residues within the
CBS, which is usually followed by basic nuclear localization
signal (NLS) (Fig. 1A). We generated point mutations in these
conserved residues by PCR with primers containing mutated
sequence. To exclude errors during the amplification of the
internal repeat sequences of LANA1, we first made cDNAs
which encompassed 1 to 1,020 nucleotides of LANA1 se-
quence with intended mutations by PCR. Then, the region
corresponding to nucleotides 1 to 820 of the wild-type LANA1
sequence cloned in pFLAG-CMV2 was replaced with the same
region carrying point mutations, taking advantage of the inter-
nal BamHI site in LANA1 cDNA. Point mutations in pFLAG-
CMV2 LANA1 derivatives were confirmed by sequencing. To
check the expression level of the LANA1 point mutants, 293T
cells were transfected with a vector expressing FLAG-tagged
LANA1 wild-type and point mutant derivatives. After 36 h,
FLAG-tagged protein was immunoprecipitated and immuno-
blotted with anti-FLAG monoclonal antibody as described pre-
viously (41). As shown in Fig. 1B, the FLAG-tagged LANA1
point mutants were expressed at a level comparable to that of
wild-type LANA1.
We next examined the subcellular localization of the
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LANA1 point mutants by an immunofluorescence assay (43).
To visualize the interphase nuclei and mitotic chromosomes,
we cotransfected the FLAG-tagged expression vectors with an
expression vector for histone 2B protein fused to N-terminal
green fluorescent protein (GFP). In a previous report (34),
GFP-fused histone was shown to behave like its natural coun-
terparts and was used to study chromosome dynamics in living
cells. As described previously (5, 14, 49), wild-type LANA1 is
localized to interphase nuclei, where it forms a heterogeneous
pattern (Fig. 2A), and associates tightly with mitotic chromo-
somes (Fig. 2B). Similar results were obtained using H3-GFP
and H4-GFP (data not shown). When we examined the
LANA1 point mutants, we found that they were localized ex-
clusively to the nucleus in interphase cells. An exception was
the RG20AA mutant, which was present in both cytoplasm and
the nucleus (Fig. 2C). In mitotic cells, however, point muta-
tions between the 8th and 13th amino acid of LANA1 com-
pletely abolished association with mitotic chromosomes (Fig.
2D). These data indicate that residues 8 to 13 of the LANA1
CBS are critical for mitotic chromosome binding. The muta-
tion of RG to AA may impair the NLS function of LANA1,
and the mutant may have access to the nucleus only after the
nuclear membrane breaks down during mitosis.
Due to the limited resolution of our immunofluorescence
assay, it was not clear whether each LANA1 point mutant
associated with the chromosome and/or occupied different sub-
nuclear locations in interphase cells. To examine this, we frac-
tionated total proteins from 293T cells transiently expressing
each FLAG-tagged LANA1 point mutant and analyzed their
distributions within cells (43). The cells were harvested 36 h
after transfection and lysed in cytoskeleton (CSK) buffer (10
mM piperazine-N,N-bis(2-ethanesulfonic acid) [pH 6.8], 100
mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA, 1 mM
dithiothreitol, 0.1 mM ATP, 0.2 mM phenylmethylsulfonyl flu-
oride, 1 mM Na3VO4, and 10 mM NaF) containing 0.5%
Triton X-100. The lysate was centrifuged at low speed, and the
supernatant was clarified by high-speed centrifugation (frac-
tion S). The pellet from the low-speed centrifugation was
washed once in CSK buffer, subjected to extensive digestion
with DNase I, and again centrifuged at low speed. The super-
natant and pellet corresponded to the DNase I-extractable
fraction (fraction C) and DNase I-resistant fraction (fraction
M), respectively. As shown in Fig. 3, the majority of wild-type
LANA1 appeared in the DNase I-resistant fraction (fraction
M). In contrast, LANA1 point mutants defective for mitotic
chromosome binding were found exclusively in the Triton
X-100-extractable fraction (fraction S). The PL17AG and
RG20AA mutants, which associate with mitotic chromosomes,
were distributed between the Triton X-100-extractable fraction
and the DNase I-resistant fraction. Interestingly, transiently
expressed FLAG-tagged EBNA-1, a functional analog of
KSHV LANA1 in the latent replication of EBV, was exclu-
sively found in the Triton X-100-extractable fraction. We also
used antibodies to examine the partitioning of endogenous
proteins during fractionation to confirm that other cellular
proteins showed a specific distribution and that each of the
FLAG-tagged LANA1 point mutants was fractionated in an
equivalent manner. Under our experimental conditions, p53
and histone proteins were exclusively found in fraction M,
while -actin was equivalently distributed to all fractions (data
not shown). These data indicate that LANA1 point mutants
defective for mitotic chromosome binding also fail to cofrac-
tionate with histone proteins in transfected cells. Since cells
from unsynchronized populations are largely engaged in inter-
FIG. 1. Construction of LANA1 point mutants. (A) Multiple sequence alignment of herpesvirus LANA1 homologues. The N-terminal amino
acid sequences are aligned. The CBS and NLS of KSHV LANA1 are shown. Conserved residues are indicated by asterisks. RRV, rhesus
rhadinovirus; BHV4, bovine herpesvirus 4; OHV2, ovine herpesvirus 2; HVS, herpesvirus saimiri; ORF, open reading frame. (B) Expression of
FLAG-tagged LANA1 point mutants in transiently transfected 293T cells.
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phase, this suggests that they have different subnuclear com-
partments during not only mitosis but also interphase, at the
time when DNA synthesis occurs.
LANA1 represses transcription from the KSHV TR by bind-
ing to sequences within the TR via its C-terminal DNA-binding
domain (6, 15, 24, 42). From the organization of the functional
domains of LANA1, it appeared likely that point mutations
within the LANA1 CBS would not alter the DNA-binding and
transcriptional repression activities of the C terminus of
LANA1. To test this expectation, we performed a transient-
reporter assay using p4TR-luc to examine the transcriptional
repression activity of the LANA1 point mutants. As shown in
Fig. 4A, all the point mutants, like wild-type LANA1, inhibited
TR-dependent transcription, although the efficiency of repres-
sion varied. The mutants defective in chromosome binding
inhibited the transcriptional activity of TR more strongly than
wild type. In contrast, the RG20AA mutant, possibly because
of its different subcellular localization during interphase, re-
pressed TR-dependent transcription less efficiently. In a par-
allel experiment, we also examined the effect of LANA1 point
FIG. 2. Subcellular localization and mitotic chromosome association of LANA1 point mutants. 293T cells grown on coverglasses were
transfected with expression vectors for FLAG-tagged wild-type or point mutants of LANA1 and GFP-fused histone. FLAG-tagged proteins were
detected with anti-FLAG monoclonal antibody and secondary rhodamine-conjugated anti-mouse antibody. (A and B) Interphase localization
(A) and mitotic chromosome association (B) of FLAG-tagged wild-type LANA1 were examined using GFP-fused histone 2B protein under a
confocal laser microscope. (C and D) Interphase localization (C) and mitotic chromosome association (D) of FLAG-tagged LANA1 point mutants
were similarly investigated.
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mutants on the transcription from pGL2-basic, a backbone
reporter of p4TR-luc (data not shown). Consistent with previ-
ous reports (23, 42, 54), LANA1 activated TR-independent
transcription up to twofold. However, point mutants defective
for mitotic chromosome binding failed to activate the tran-
scription from pGL2-basic, partly explaining their enhanced
transcriptional repression activities on TR-dependent tran-
scription.
FIG. 2—Continued.
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In order to examine the ability of the LANA1 point mutants
to promote the replication of a KSHV TR-containing plasmid
in a transient-replication assay, we cotransfected 293T cells
with p4TR-luc containing four TR sequences of the KSHV
genome and pGL2-basic, together with expression vectors for
the wild-type or point mutants of LANA1. The cells were split
36 h after transfection to remove free DNA and harvested 96 h
after transfection. Low-molecular-weight DNA was purified
FIG. 2—Continued.
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from the transfected cells as described previously (42). Using
the methylation-sensitive restriction enzyme DpnI, which does
not cut the plasmid DNA replicated in mammalian cells, we
estimated the extent of replication of the TR-containing plas-
mid in the presence of the wild-type or point mutant LANA1.
We included nonreplicating pGL2-basic as an internal control
to monitor the efficiency of transfection and of plasmid recov-
ery, as well as the completeness of the digestion of unrepli-
cated DNA by DpnI. As shown in Fig. 4B, mutants of LANA1
defective in binding to mitotic chromosomes did not support
the replication of the TR-containing plasmid. Longer exposure
could hardly reveal any DpnI-resistant plasmid in the presence
of chromosome-binding-defective mutants, making it difficult
to quantitatively analyze the decrease in the relative level of
replication (data not shown).
In order to survive in latently infected cells, DNA viruses
with extrachromosomal genomes must replicate their DNA
and ensure segregation of the daughter molecules to the two
progeny cells. In the case of papillomavirus a viral helicase, E1
(67), in concert with a viral auxiliary protein, E2, unwinds the
viral origin of replication and initiates DNA synthesis (13, 17,
18, 62). However, long-term maintenance of a viral oriP-con-
FIG. 3. Biochemical fractionation of LANA1 point mutants. 293T
cells in 60-mm dishes were transfected with 4 g of expression vectors
encoding FLAG-tagged wild-type LANA1 or point mutant derivatives
and harvested 36 h after transfection. Total proteins were fractionated
as described in the text. LANA1 was detected by immunoblotting with
rabbit polyclonal anti-LANA1 serum. Distribution of transiently ex-
pressed FLAG-tagged EBNA-1 was similarly revealed by immunoblot-
ting with anti-FLAG monoclonal antibody. WT, wild type; fraction S,
Triton X-100-extractable fraction; fraction C, DNase I-extractable
fraction; fraction M, DNase I-resistant fraction.
FIG. 4. Transcription and replication activities of LANA1 point
mutants. (A) 293T cells in 60-mm dishes were cotransfected with 1 g
of p4TR-luc and 4 g of blank or FLAG-tagged LANA1 expression
vector encoding wild type or point mutants. After 36 h, cells were
harvested and luciferase assays were performed (42). The relative
activation was calculated by normalizing to the luciferase activity ob-
tained with the blank vector. The results are averages of three inde-
pendent experiments, with standard deviations depicted by the error
bars. (B) 293T cells in 100-mm dishes were transiently transfected with
2 g of p4TR-luc containing four copies of KSHV TR, 2 g of pGL2-
basic as a nonreplicating internal control, and 8 g of expression vector
for FLAG-tagged LANA1 or its point mutants. Low-molecular-weight
DNA was purified 96 h after transfection and subjected to digestion
with Alw44I alone (left) or Alw44I/DpnI (right). Digested DNA was
separated on an 0.8% agarose gel, transferred to a nylon membrane,
and detected by Southern blotting with a luciferase-specific probe.
Input, 10% of the DNA used in the Alw44I/DpnI digestion.
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taining plasmid requires an additional viral cis-acting element
designated a minichromosome maintenance element (MME)
(48). The MME is located within the long control region, which
is distinct from the replication origin and contains multiple
high-affinity E2-binding sites. Accumulating data suggest that
chromatin-bound E2 tethers the viral genome to the host chro-
mosome via the MME, thereby ensuring equipartition of the
replicated viral genomes at mitosis (8, 31, 39, 61, 63). In the
case of EBV, two cis elements constitute the origin of replica-
tion during latent replication (44, 46, 53, 68). These are mem-
bers of a family of repeat (FR) and dyad symmetry sequences
separated by 1 kb within the EBV genome. Both sequences
contain binding sites for EBNA-1 (2, 4, 52), the viral trans-
acting element required for the latent replication of EBV (69).
In contrast to papillomavirus E1, EBNA-1 does not have any
enzymatic activity for DNA replication, but instead it recruits
a prereplicative complex to the viral oriP (12, 19, 56). DNA
synthesis initiates at or near low-affinity EBNA-1-binding sites
within dyad symmetry sequences (21), and these latter are
necessary and sufficient for transient DNA replication medi-
ated by EBNA-1 (27, 38, 44, 53). However, the stable mainte-
nance of a plasmid containing the EBV oriP requires, in ad-
dition, multiple high-affinity EBNA-1-binding sites within FR
sequences (1, 38, 46, 64). As in the case of papillomavirus E2,
EBNA-1 associates with host chromosomes (45), and it has
been suggested that the action of the FR in retaining the
plasmid involves the viral genome hitchhiking on the host
chromosome via EBNA-1.
It seems likely that KSHV has evolved a similar chromo-
some-tethering mechanism for its persistence in host cells (5,
14, 49, 59) and that LANA1 is responsible not only for the
stable maintenance but also for the replication of KSHV TR-
containing plasmids (26, 28, 42). In a transient-replication as-
say using a panel of LANA1 deletion mutants, the minimal
domain of LANA1 able to support the replication of a TR-
containing plasmid was identified as LANA1 23-950, which
contains the N-terminal CBS in addition to the C-terminal
DNA-binding and dimerization domain (Lim et al., submit-
ted). The requirement for the N-terminal CBS for replication
activity was unexpected, since (i) the N-terminal CBS was
thought to function mainly in the equal segregation and nu-
clear retention of the viral genome and (ii) the C terminus of
LANA1, which can dimerize, bind TR sequences, and interact
with the components of prereplicative complex (42), seemed
likely to be sufficient for the replication activity of LANA1. In
the present work we have generated several point mutations in
the N-terminal CBS and characterized their activity in order to
confirm that the replication activity of LANA1 requires its
ability to bind to the chromosome. We found that point mu-
tants, which were unable to associate with mitotic chromo-
somes, also failed to exclusively cofractionate with histone pro-
teins in an unsynchronized population and facilitate the
transient replication of a KSHV TR-containing plasmid, sup-
porting the idea that chromosome binding of LANA1 is a
prerequisite for its replication activity. It is noteworthy that all
LANA1 point mutations used in this study did not abolish the
nuclear localization in interphase cells (with some variation in
the RG20AA mutant), the transcriptional repression activity of
TR-dependent transcription, and the association with SAP30,
which was previously shown to interact with the N terminus of
LANA1 (36) (data not shown). Therefore, it seems unlikely
that point mutations in the LANA1 CBS globally affect its
structure or stability. The following evidence also argues
against the possibility that the failure of the mutants defective
in chromosome binding to support the replication of a KSHV
TR-containing plasmid results from their inability to retain the
KSHV TR-containing plasmid in the nucleus when nuclear
membranes are reassembled at the end of mitosis. First, the
LANA1 point mutations have an all-or-nothing effect on plas-
mid replication, whereas if the replication activity were intact
but only the chromosome tethering and nuclear retention ac-
tivities were abolished, the replication activities of those mu-
tants should have been reduced rather than completely abol-
ished. Second, trans-acting elements of papillomavirus and
EBV lacking chromosome-binding and/or plasmid mainte-
nance activity retain replication activity comparable to wild
type in transient-replication assays (29, 39, 60, 65, 66), although
there are some reports that mitotic chromosome binding of
EBV EBNA-1 is also important for its replication activity (32,
58). Furthermore, viral cis-acting elements responsible for
plasmid retention that probably act by tethering themselves to
chromosomes are not required for replication activity in those
systems (27, 38, 44, 48, 53). These data imply that defects in
segregation and nuclear retention should not affect the repli-
cation of viral oriP-containing plasmids in transient-replication
assays.
Instead we favor the idea that the N-terminal CBS of
LANA1 targets TR-containing plasmids to the host chromo-
somes by interacting with chromatin-bound cellular factors.
These could be replication factors specifically required for
initiating replication from the KSHV TR or auxiliary factors
facilitating the stable assembly of a prereplicative complex on
the viral origin of DNA replication. MeCP-2 and H1 could be
proteins targeted by the LANA1 CBS (14, 37, 59), although
their functional relevance in the latent DNA replication of
KSHV remains to be further investigated. While it cannot be
excluded that the possibility that different cellular proteins are
individually involved in DNA replication and the chromosome
association activity of LANA1, our data suggest that the rep-
lication activity of LANA1 is tightly coupled to its chromosome
association, and the replication of the latent KSHV genome
may be intimately tied up with its equal segregation and nu-
clear retention. Such a mechanism for ensuring the persistence
of the KSHV genome in latently infected cells would be unique
among DNA viruses. In papillomavirus and EBV, replication
of the viral genome and its partitioning are independent events
mediated by different viral cis elements, and multiple high-
affinity binding sites for the viral trans-acting element are re-
quired for stable maintenance of viral oriP-containing plas-
mids. In contrast, the fact that a single unit of KSHV TR is
sufficient for plasmid persistence (6), but does not have mul-
tiple high-affinity binding sites for LANA1, may explain the
peculiar mechanism of replication of latent KSHV.
While this report was under review, Barbera et al. (7) re-
ported their point mutational analysis in chromosome associ-
ation, DNA replication, and plasmid maintenance activity of
LANA1. They sequentially replaced residues within the
LANA1 CBS with alanine and obtained data consistent with
our study.
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